Literature DB >> 22882377

B cell and T cell immunity in the female genital tract: potential of distinct mucosal routes of vaccination and role of tissue-associated dendritic cells and natural killer cells.

F Anjuère1, S Bekri, F Bihl, V M Braud, N Cuburu, C Czerkinsky, C Hervouet, C Luci.   

Abstract

The female genital mucosa constitutes the major port of entry of sexually transmitted infections. Most genital microbial pathogens represent an enormous challenge for developing vaccines that can induce genital immunity that will prevent their transmission. It is now established that long-lasting protective immunity at mucosal surfaces has to involve local B-cell and T-cell effectors as well as local memory cells. Mucosal immunization constitutes an attractive way to generate systemic and genital B-cell and T-cell immune responses that can control early infection by sexually transmitted pathogens. Nevertheless, no mucosal vaccines against sexually transmitted infections are approved for human use. The mucosa-associated immune system is highly compartmentalized and the selection of any particular route or combinations of routes of immunization is critical when defining vaccine strategies against genital infections. Furthermore, mucosal surfaces are complex immunocompetent tissues that comprise antigen-presenting cells and also innate immune effectors and non-immune cells that can act as 'natural adjuvants' or negative immune modulators. The functions of these cells have to be taken into account when designing tissue-specific antigen-delivery systems and adjuvants. Here, we will discuss data that compare different mucosal routes of immunization to generate B-cell and T-cell responses in the genital tract, with a special emphasis on the newly described sublingual route of immunization. We will also summarize data on the understanding of the effector and induction mechanisms of genital immunity that may influence the development of vaccine strategies against genital infections.
© 2012 The Authors. Clinical Microbiology and Infection © 2012 European Society of Clinical Microbiology and Infectious Diseases.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22882377     DOI: 10.1111/j.1469-0691.2012.03995.x

Source DB:  PubMed          Journal:  Clin Microbiol Infect        ISSN: 1198-743X            Impact factor:   8.067


  5 in total

1.  Intranasal nanoemulsion-adjuvanted HSV-2 subunit vaccine is effective as a prophylactic and therapeutic vaccine using the guinea pig model of genital herpes.

Authors:  David I Bernstein; Rhonda D Cardin; Fernando J Bravo; Tarek Hamouda; Derek A Pullum; Gary Cohen; Vira Bitko; Ali Fattom
Journal:  Vaccine       Date:  2019-09-09       Impact factor: 3.641

2.  Flagellin is a strong vaginal adjuvant of a therapeutic vaccine for genital cancer.

Authors:  Shee Eun Lee; Seol Hee Hong; Vivek Verma; Youn Suhk Lee; Tra-My Nu Duong; Kwangjoon Jeong; Saji Uthaman; Young Chul Sung; Jae-Tae Lee; In-Kyu Park; Jung-Joon Min; Joon Haeng Rhee
Journal:  Oncoimmunology       Date:  2015-08-24       Impact factor: 8.110

3.  Sublingual Priming with a HIV gp41-Based Subunit Vaccine Elicits Mucosal Antibodies and Persistent B Memory Responses in Non-Human Primates.

Authors:  Selma Bekri; Pierre Bourdely; Carmelo Luci; Nathalie Dereuddre-Bosquet; Bin Su; Frédéric Martinon; Véronique M Braud; Irene Luque; Pedro L Mateo; Sara Crespillo; Francisco Conejero-Lara; Christiane Moog; Roger Le Grand; Fabienne Anjuère
Journal:  Front Immunol       Date:  2017-02-01       Impact factor: 7.561

4.  Intranasal Vaccination Affords Localization and Persistence of Antigen-Specific CD8⁺ T Lymphocytes in the Female Reproductive Tract.

Authors:  Shailbala Singh; Kimberly S Schluns; Guojun Yang; Scott M Anthony; Michael A Barry; K Jagannadha Sastry
Journal:  Vaccines (Basel)       Date:  2016-03-17

5.  NKp46+ Innate Lymphoid Cells Dampen Vaginal CD8 T Cell Responses following Local Immunization with a Cholera Toxin-Based Vaccine.

Authors:  Carmelo Luci; Selma Bekri; Franck Bihl; Jonathan Pini; Pierre Bourdely; Kelly Nouhen; Angélique Malgogne; Thierry Walzer; Véronique M Braud; Fabienne Anjuère
Journal:  PLoS One       Date:  2015-12-02       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.